Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Insight can strike in unexpected places. For Ray Deshaies, SVP of Global Research at Amgen, it tends to come high up in the sky. “Several of the key insights I've had in my life have occurred on airplanes,” says Deshaies. Flying back from Denmark after Amgen’s acquisition of Nuevolution in 2019, for example, he noticed a trend in his company’s preclinical portfolio that may foretell the future of industry writ large: the rise of multispecific therapeutics that drive induced proximity between otherwise disparate biological players.